Sun Pharmaceutical Industries Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Revital

Volini

Abzorb

Pepfiz

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Sun Pharmaceutical Industries Ltd sees positive momentum with NCLT approving subsidiary mergers, strong prescription supply in the US, and favorable market conditions boosting stock prices.

Sun Pharma Gains Amid Positive Market Trends - 09 Oct, 2025

Sun Pharmaceutical Industries Ltd sees a positive shift in investor sentiment as Citi maintains a Buy rating with a target price of ₹2,180. The easing of pricing concerns following the Pfizer-Trump deal has boosted confidence in Sun Pharma's growth prospects, leading to a notable rise in share prices throughout the day.

Sun Pharma Gains on Positive Analyst Ratings and Pfizer Deal - 01 Oct, 2025

Sun Pharmaceutical Industries Ltd is recalling 1,870 kits of a renal imaging agent due to failed tests. Additionally, analysts highlight limited earnings impact from new US tariffs affecting patented drugs.

Sun Pharma Faces Recall and US Tariff Risks - 28 Sep, 2025

Sun Pharmaceutical Industries Ltd may encounter challenges as its US drug sales reached $1.1 billion in FY25, constituting 17% of total revenue, amid tariff concerns.

Sun Pharma Faces Revenue Challenges in US Market - 27 Sep, 2025

Sun Pharma's stock fell sharply following the US announcement of 100% tariffs on branded drugs. Analysts predict limited earnings impact, but downside risks remain significant.

Sun Pharma Faces Tariff Challenges Amid Stock Decline - 26 Sep, 2025

Brokerages have differing views on Sun Pharma's stock. Morgan Stanley is bullish with a target of ₹1,948, while Nuvama maintains a cautious Hold at ₹1,830, citing productivity concerns. Both expect growth in revenue and profit over the next few years.

Divergent Brokerage Ratings on Sun Pharma Stock - 25 Sep, 2025

Sun Pharmaceutical Industries Ltd showcases strong growth potential with a completed Sonidegib study, positive Q1 results, and buy ratings from brokerages targeting ₹1,960 and ₹2,070.

Sun Pharma's Growth Strategies and Study Completion - 24 Sep, 2025

Citi has reaffirmed Sun Pharmaceutical Industries as a top pick, setting a target price of Rs 2,180, anticipating significant growth in innovation revenues. Despite a 14% decline year-to-date, the stock shows potential upside.

Citi Bullish on Sun Pharma Amid Revenue Growth - 18 Sep, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Revenue is up for the last 2 quarters, 13.57K Cr → 14.31K Cr (in ₹), with an average increase of 5.2% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Netprofit is up for the last 2 quarters, 2.14K Cr → 2.27K Cr (in ₹), with an average increase of 5.7% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

In the last 1 month, SUNPHARMA stock has moved up by 2.4%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Mutual Funds have increased holdings from 12.21% to 12.63% in Jun 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

Promoters holdings remained unchanged at 54.48% of holdings in Jun 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 1 year, Divis Laboratories Ltd has given 8.6% return, outperforming this stock by 20.8%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Against Peers

In the last 3 years, Torrent Pharmaceuticals Ltd has given 123.6% return, outperforming this stock by 54.3%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Retail Investor have decreased holdings from 8.87% to 8.77% in Jun 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Foreign Institutions have decreased holdings from 17.96% to 17.26% in Jun 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

S&P BSE Low Volatility

S&P BSE 250 LargeMidCap

Nifty Healthcare

S&P BSE Largecap

BSE 100

S&P BSE 100 ESG

BSE 500

BSE MFG

BSE Healthcare

NIFTY 50

S&P BSE Dividend Stability

BSE 200

Nifty LargeMidcap 250

NIFTY 100

S&P BSE SENSEX 50

S&P BSE 100 LargeCap TMC

Nifty 200

NIFTY PHARMA

SENSEX

Nifty100 Low Volatility 30

Nifty100 Eq Weig

Nifty 500

ICICI Prudential Value Fund Direct Plan Growth

ICICI Prudential Equity & Debt Fund Direct Plan Growth

ICICI Prudential Large Cap Fund Direct Plan Growth

ICICI Prudential India Opportunities Fund Direct Growth

HDFC Balanced Advantage Fund Direct Plan Growth Option

Sun Pharmaceutical Industries Ltd’s net profit fell -19.64% since last year same period to ₹2,278.63Cr in the Q1 2025-2026. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated 5.99% jump in its net profits since last 3-months.

Sun Pharmaceutical Industries Ltd Earnings Results

In the quarter ending March 2025, Sun Pharmaceutical Industries Ltd has declared dividend of ₹5.50 per share on 22 May 2025 - translating a dividend yield of 1.27%.

Name	Value	Action
MACD level (12,26)	-0.01	Bullish
CCI (20)	-348.68	Bullish
RSI (14)	52.92	Neutral
Momentum (10)	1.2	Bearish
ADI (14)	17.95	Neutral
Ultimate Oscillator (7,14,28)	78.3	Bullish

Name	Value	Action
SMA (20)	1679.1	Bullish
EMA (20)	1679.31	Bullish
VWMA (20)	1679.13	Bullish
SMA (50)	1679.79	Bearish
EMA (50)	1679.69	Bullish
SMA (200)	1677.46	Bullish
EMA (200)	1676.78	Bullish
KAMA (200)	1680.4	Bearish
DEMA (200)	1682.95	Bearish

Sun Pharmaceutical Industries Ltd (SUNPHARMA)

Summary

Overall

Oscillators

Moving Averages